Xi-Wen Bi

792 total citations
24 papers, 577 citations indexed

About

Xi-Wen Bi is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Xi-Wen Bi has authored 24 papers receiving a total of 577 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 18 papers in Pathology and Forensic Medicine and 7 papers in Immunology. Recurrent topics in Xi-Wen Bi's work include Lymphoma Diagnosis and Treatment (18 papers), Viral-associated cancers and disorders (16 papers) and Immune Cell Function and Interaction (7 papers). Xi-Wen Bi is often cited by papers focused on Lymphoma Diagnosis and Treatment (18 papers), Viral-associated cancers and disorders (16 papers) and Immune Cell Function and Interaction (7 papers). Xi-Wen Bi collaborates with scholars based in China and United States. Xi-Wen Bi's co-authors include Wen-wen Zhang, Zhiming Li, Yi Xia, Zhong-Jun Xia, Wen-Qi Jiang, Jing‐Hua Wang, Liang Wang, Peng Sun, Hua Wang and Panpan Liu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Xi-Wen Bi

24 papers receiving 575 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xi-Wen Bi China	12	397	354	199	73	70	24	577
Gan‐di Li China	13	342 0.9×	371 1.0×	141 0.7×	128 1.8×	82 1.2×	65	641
Wing-Yan Au China	5	531 1.3×	658 1.9×	315 1.6×	49 0.7×	99 1.4×	5	755
F Loong China	11	282 0.7×	386 1.1×	154 0.8×	168 2.3×	55 0.8×	19	612
Sverker Hasselblom Sweden	14	209 0.5×	320 0.9×	145 0.7×	103 1.4×	79 1.1×	25	494
Yayan Zhang United States	7	331 0.8×	142 0.4×	148 0.7×	65 0.9×	42 0.6×	10	440
Barbara Vannata Italy	12	237 0.6×	347 1.0×	93 0.5×	46 0.6×	60 0.9×	23	584
Manuel F. Rosado United States	10	249 0.6×	333 0.9×	87 0.4×	58 0.8×	113 1.6×	14	491
Jean‐Marc Schiano de Colella France	13	261 0.7×	263 0.7×	194 1.0×	62 0.8×	134 1.9×	41	600

Countries citing papers authored by Xi-Wen Bi

Since Specialization

Citations

This map shows the geographic impact of Xi-Wen Bi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xi-Wen Bi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xi-Wen Bi more than expected).

Fields of papers citing papers by Xi-Wen Bi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xi-Wen Bi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xi-Wen Bi. The network helps show where Xi-Wen Bi may publish in the future.

Co-authorship network of co-authors of Xi-Wen Bi

This figure shows the co-authorship network connecting the top 25 collaborators of Xi-Wen Bi. A scholar is included among the top collaborators of Xi-Wen Bi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xi-Wen Bi. Xi-Wen Bi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yuan, Jing, Xi-Wen Bi, Hua Xin, et al.. (2025). Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial. The Lancet Oncology. 26(12). 1575–1583. 1 indexed citations

Li, Yiqun, De Zeng, Xi-Wen Bi, et al.. (2024). Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China.. Journal of Clinical Oncology. 42(16_suppl). 1 indexed citations

Sun, Peng, Cui Chen, Yi Xia, et al.. (2019). Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA. Journal of Cancer. 10(2). 323–331. 34 indexed citations

Bi, Xi-Wen, Xuewen Zhang, Panpan Liu, et al.. (2019). Characteristics, Prognostic Factors, and Survival of Patients with NK/T-Cell Lymphoma of Non-upper Aerodigestive Tract: A 17-Year Single-Center Experience. Cancer Research and Treatment. 51(4). 1557–1567. 7 indexed citations

Bi, Xi-Wen, et al.. (2018). The Clinical Utility of Circulating Epstein-Barr Virus DNA Concentrations in NK/T-Cell Lymphoma: A Meta-Analysis. Disease Markers. 2018. 1–8. 8 indexed citations

Bi, Xi-Wen, Panpan Liu, Yu Wang, et al.. (2018). Expressions and prognostic values of the <em>E2F</em> transcription factors in human breast carcinoma. Cancer Management and Research. Volume 10. 3521–3532. 34 indexed citations

Wang, Jing‐Hua, Xi-Wen Bi, Pengfei Li, et al.. (2017). Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK/T-cell Lymphoma, Nasal Type. Journal of Cancer. 8(5). 793–800. 14 indexed citations

Bi, Xi-Wen, et al.. (2016). The pretreatment albumin to globulin ratio predicts survival in patients with natural killer/T-cell lymphoma. PeerJ. 4. e1742–e1742. 24 indexed citations

Liu, Panpan, Yi Xia, Xi-Wen Bi, et al.. (2016). Racial patterns of patients with primary mediastinal large B-cell lymphoma. Medicine. 95(27). e4054–e4054. 33 indexed citations

10.

Sun, Peng, Fei Zhang, Chao Ren, et al.. (2016). Prognostic impact of body mass index stratified by smoking status in patients with esophageal squamous cell carcinoma. OncoTargets and Therapy. Volume 9. 6389–6397. 9 indexed citations

11.

Zhang, Xi, Jia-Jia Huang, Yi Xia, et al.. (2016). High risk of deep vein thrombosis associated with peripherally inserted central catheters in lymphoma. Oncotarget. 7(23). 35404–35411. 17 indexed citations

12.

Wang, Feng-Hua, Cui Chen, Fei Zhang, et al.. (2016). Combined heavy smoking and drinking predicts overall but not disease-free survival after curative resection of locoregional esophageal squamous cell carcinoma. OncoTargets and Therapy. Volume 9. 4257–4264. 11 indexed citations

13.

Bi, Xi-Wen, Wen-wen Zhang, Peng Sun, et al.. (2016). High Pretreatment D-Dimer Levels Correlate with Adverse Clinical Features and Predict Poor Survival in Patients with Natural Killer/T-Cell Lymphoma. PLoS ONE. 11(3). e0152842–e0152842. 11 indexed citations

14.

Bi, Xi-Wen, Hua Wang, Wen-wen Zhang, et al.. (2016). PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. Journal of Hematology & Oncology. 9(1). 109–109. 238 indexed citations

15.

Nie, Man, Xi-Wen Bi, Wen-wen Zhang, et al.. (2016). Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphoma. Scientific Reports. 6(1). 23996–23996. 6 indexed citations

16.

Huang, Jia-Jia, Yi Xia, Yu Wang, et al.. (2015). Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis. PLoS ONE. 10(7). e0133973–e0133973. 18 indexed citations

17.

Bi, Xi-Wen, Yi Xia, Wen-wen Zhang, et al.. (2015). Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma. Annals of Hematology. 94(9). 1525–1533. 34 indexed citations

18.

Yang, Hang, Yu Wang, Jing Zhan, et al.. (2015). Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110δ, for treating relapsed or refractory non-Hodgkin's lymphoma. Oncotarget. 6(41). 44049–44056. 3 indexed citations

19.

Nie, Man, Yu Wang, Xi-Wen Bi, et al.. (2015). Effect of rituximab on adult Burkitt’s lymphoma: a systematic review and meta-analysis. Annals of Hematology. 95(1). 19–26. 11 indexed citations

20.

Bi, Xi-Wen, Wen-wen Zhang, Zhiming Li, et al.. (2015). The extent of local tumor invasion predicts prognosis in stage IE nasal natural killer/T-cell lymphoma: a novel T staging system for risk stratification. Annals of Hematology. 94(9). 1515–1524. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact